nerve growth factor Search Results


90
Cusabio elisa kit
Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Rat+Nerve+growth+factor%2CNGF+ELISA+kit/10__1007_slash_s43994___022___00001___w-89-0-2
Average 90 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Rockland Immunochemicals anti vgf
Anti Vgf, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/VGF+Antibody/pmc09138053-42-7-4
Average 93 stars, based on 1 article reviews
anti vgf - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
Alomone Labs neuronal differentiation assay
Neuronal Differentiation Assay, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Native+mouse+NGF+2%2E5S+protein/pmc06756257-118-2-13
Average 95 stars, based on 1 article reviews
neuronal differentiation assay - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Alomone Labs nerve growth factor 7s
Nerve Growth Factor 7s, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Native+mouse+NGF+7S+protein/pmc06080895-79-30-33
Average 95 stars, based on 1 article reviews
nerve growth factor 7s - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Alomone Labs anti prongf
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Anti Prongf, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Anti-proNGF+Antibody/pm36675126-222-4-10
Average 93 stars, based on 1 article reviews
anti prongf - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Alomone Labs mouse ngf biotin
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Mouse Ngf Biotin, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/mouse+NGF+2%2E5S-Biotin/pmc09680784-108-12-15
Average 93 stars, based on 1 article reviews
mouse ngf biotin - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Alomone Labs trka
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Trka, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Anti-TrkA+(extracellular)+Antibody/pmc09321700-6-0-2
Average 94 stars, based on 1 article reviews
trka - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Alomone Labs ngf
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Ngf, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Anti-NGF+Antibody/pmc07343331-124-33-34
Average 94 stars, based on 1 article reviews
ngf - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
Alomone Labs nt 3
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Nt 3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Recombinant+human+Neurotrophin-3+(NT-3)+protein/bio_rxiv__2023__10__28__564305-45-25-26
Average 95 stars, based on 1 article reviews
nt 3 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

94
Alomone Labs rabbit anti nt3
Data: mean ± SD. ( A , B ) Intraperitoneal injection of paclitaxel produced mechanical allodynia as evidenced by the increases in paw withdrawal frequencies in response to 0.07 g ( A ) and 0.4 g ( B ) von Frey filaments on the left side. n = 12 mice/time point. * P < 0.05, ** P < 0.01 versus the vehicle-treated group at the corresponding time points by two-way ANOVA with repeated measures followed by post hoc Tukey test. ( C , D ) The levels of <t>Nt3</t> mRNA ( C ) and NT3 protein ( D ) in L3/4 DRGs on different days as indicated after the first injection of paclitaxel or vehicle. D: representative Western blots (left) and a summary of the densitometric analysis (right) are shown. n = 3 biological repeats (3 mice)/time point. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( E ) The amount of NT3 protein in the L3/4 spinal cord on different days as indicated after the first injection of paclitaxel. n = 3 biological repeated (3 mice)/time point. P > 0.05 by one-way ANOVA followed by post hoc Tukey test. .
Rabbit Anti Nt3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Anti-Neurotrophin+3+(NT-3)+Antibody/pmc11094060-308-4-7
Average 94 stars, based on 1 article reviews
rabbit anti nt3 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

ngf  (Cusabio)
92
Cusabio ngf
Clinical characteristics of subjects.
Ngf, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Human+Nerve+growth+factor%2CNGF+ELISA+kit/pmc07501055-75-29-32
Average 92 stars, based on 1 article reviews
ngf - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

94
ABclonal Biotechnology ngf
MSM-DTM adsorbs inflammatory cytokines, suppresses TSPCs inflammation and senescence, and promotes tenogenic differentiation and migration (A) The remaining concentrations of <t>TNF-α,</t> <t>IL-1β,</t> IL-6, IFN-γ, LPS, and <t>NGF</t> were detected by ELISA after co-culture with different concentrations of MSM. (B and C) RT-qPCR of IL-6 and CCL-2 in TSPCs under different treatments. (D) Western blot of COL1A2, MMP3, and TNMD. (E) ELISA of TNF-α, IL-6, and IFN-γ in supernatants. (F)Western blot of p16 and p21 after 7 days of treatment. (G) β-Galactosidase staining analysis after 7 days of treatment. Scale bars, 100 μm. (H and I) Immunofluorescence and quantification of TNMD and TNC after 14-day treatment. Scale bars, 50 μm. (J) Relative mRNA expression of tenogenic differentiation markers SCX and TNC. (K and L) Representative images and quantification of Transwell assay. Scale bars, 100 μm. (M and N) Representative images and quantification of wound healing assay. Scale bars, 100 μm. Statistical comparisons were performed with one-way ANOVA with Tukey’s multiple comparisons test. Data are presented as the mean ± SD, n = 3. Ns, no significance, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 between groups.
Ngf, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve+growth+factor/Human+Beta-nerve+growth+factor+ELISA+Kit%EF%BC%88NGFB%EF%BC%89/pmc13522776-450-25-26
Average 94 stars, based on 1 article reviews
ngf - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF (anti-proNGF, 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.

Journal: International journal of molecular sciences

Article Title: ProNGF Expression and Targeting in Glioblastoma Multiforme.

doi: 10.3390/ijms24021616

Figure Lengend Snippet: Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF (anti-proNGF, 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.

Article Snippet: Sections were labelled for anti-proNGF (0.8 μg/mL, catalogue number ANT005, Alomone labs, Jerusalem, Israel).

Techniques: Methylation, Control, Blocking Assay

Figure 5. In vivo targeting of proNGF in a mouse model of GBM. A xenograft mouse model of GBM was used. The human U87MG cells were injected subcutaneously between the shoulder blades of BALB/c nude mice, along with blocking anti-proNGF antibody (12 µg, intratumoral injection, twice a week for 4 weeks) and/or TMZ (50 mg/kg body weight, IP daily for 5 days) treatment for a 4-week course. (A) Representative photographs of U87MG tumors excised from mice after 4 weeks of treatment. Scale bar, 5 mm. (B) The growth curves of U87MG tumors in BALB/c nude mice (n = 9 for each group). (C) Comparison of volume of U87MG tumors harvested from mice treated with blocking anti-proNGF antibody and/or TMZ for 4 weeks. (D) Kaplan-Meier survival curves of BALB/c nude mice treated with anti-proNGF antibody and/or TMZ. Vehicle control vs. anti-proNGF: p = 0.0639; Vehicle control vs. TMZ: p < 0.0001; Vehicle control vs. anti-proNGF + TMZ: p = 0.0003; Anti-proNGF vs. anti-proNGF + TMZ: p = 0.0160, TMZ vs. anti-proNGF + TMZ: p = 0.8515. Data shown are the mean ± SD of tumors with 9 mice per treatment group. ProNGF: precursor for nerve growth factor, TMZ: Temozolomide. Vehicle control: PBS (vehicle control for anti-proNGF) + 5%GMSO + 30% Polyethylene glycol 300 (PEG300) + double-distilled H2O (vehicle control for TMZ); anti-proNGF: anti-proNGF + 5%GMSO + 30% PEG300 + double-distilled H2O (vehicle control for TMZ); TMZ: TMZ + PBS (vehicle control for anti-proNGF); anti-proNGF + TMZ: anti-proNGF + TMZ.

Journal: International journal of molecular sciences

Article Title: ProNGF Expression and Targeting in Glioblastoma Multiforme.

doi: 10.3390/ijms24021616

Figure Lengend Snippet: Figure 5. In vivo targeting of proNGF in a mouse model of GBM. A xenograft mouse model of GBM was used. The human U87MG cells were injected subcutaneously between the shoulder blades of BALB/c nude mice, along with blocking anti-proNGF antibody (12 µg, intratumoral injection, twice a week for 4 weeks) and/or TMZ (50 mg/kg body weight, IP daily for 5 days) treatment for a 4-week course. (A) Representative photographs of U87MG tumors excised from mice after 4 weeks of treatment. Scale bar, 5 mm. (B) The growth curves of U87MG tumors in BALB/c nude mice (n = 9 for each group). (C) Comparison of volume of U87MG tumors harvested from mice treated with blocking anti-proNGF antibody and/or TMZ for 4 weeks. (D) Kaplan-Meier survival curves of BALB/c nude mice treated with anti-proNGF antibody and/or TMZ. Vehicle control vs. anti-proNGF: p = 0.0639; Vehicle control vs. TMZ: p < 0.0001; Vehicle control vs. anti-proNGF + TMZ: p = 0.0003; Anti-proNGF vs. anti-proNGF + TMZ: p = 0.0160, TMZ vs. anti-proNGF + TMZ: p = 0.8515. Data shown are the mean ± SD of tumors with 9 mice per treatment group. ProNGF: precursor for nerve growth factor, TMZ: Temozolomide. Vehicle control: PBS (vehicle control for anti-proNGF) + 5%GMSO + 30% Polyethylene glycol 300 (PEG300) + double-distilled H2O (vehicle control for TMZ); anti-proNGF: anti-proNGF + 5%GMSO + 30% PEG300 + double-distilled H2O (vehicle control for TMZ); TMZ: TMZ + PBS (vehicle control for anti-proNGF); anti-proNGF + TMZ: anti-proNGF + TMZ.

Article Snippet: Sections were labelled for anti-proNGF (0.8 μg/mL, catalogue number ANT005, Alomone labs, Jerusalem, Israel).

Techniques: In Vivo, Xenograft Assay, Injection, Blocking Assay, Comparison, Control

Data: mean ± SD. ( A , B ) Intraperitoneal injection of paclitaxel produced mechanical allodynia as evidenced by the increases in paw withdrawal frequencies in response to 0.07 g ( A ) and 0.4 g ( B ) von Frey filaments on the left side. n = 12 mice/time point. * P < 0.05, ** P < 0.01 versus the vehicle-treated group at the corresponding time points by two-way ANOVA with repeated measures followed by post hoc Tukey test. ( C , D ) The levels of Nt3 mRNA ( C ) and NT3 protein ( D ) in L3/4 DRGs on different days as indicated after the first injection of paclitaxel or vehicle. D: representative Western blots (left) and a summary of the densitometric analysis (right) are shown. n = 3 biological repeats (3 mice)/time point. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( E ) The amount of NT3 protein in the L3/4 spinal cord on different days as indicated after the first injection of paclitaxel. n = 3 biological repeated (3 mice)/time point. P > 0.05 by one-way ANOVA followed by post hoc Tukey test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Intraperitoneal injection of paclitaxel produced mechanical allodynia as evidenced by the increases in paw withdrawal frequencies in response to 0.07 g ( A ) and 0.4 g ( B ) von Frey filaments on the left side. n = 12 mice/time point. * P < 0.05, ** P < 0.01 versus the vehicle-treated group at the corresponding time points by two-way ANOVA with repeated measures followed by post hoc Tukey test. ( C , D ) The levels of Nt3 mRNA ( C ) and NT3 protein ( D ) in L3/4 DRGs on different days as indicated after the first injection of paclitaxel or vehicle. D: representative Western blots (left) and a summary of the densitometric analysis (right) are shown. n = 3 biological repeats (3 mice)/time point. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( E ) The amount of NT3 protein in the L3/4 spinal cord on different days as indicated after the first injection of paclitaxel. n = 3 biological repeated (3 mice)/time point. P > 0.05 by one-way ANOVA followed by post hoc Tukey test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Injection, Produced, Western Blot

Data: mean ± SD. ( A , B ) Representative images of in situ hybridization histochemistry (ISHH) for Nt3 mRNA (red) and immunohistochemistry for β-tubulin III (green; A ) or glutamine synthetase (GS; green; B ) in the L3/4 DRGs 14 days after the first paclitaxel or vehicle injection. Cellular nuclei were labeled by 4’, 6-diamidino-2- phenylindole (DAPI; blue). n = 9–12 sections from three mice/group. * P < 0.05 by two-tailed unpaired Student t test. Scale bars: 50 µm. ( C ) Size distribution of Nt3 mRNA-labeled neuronal somata in the L3/4 DRGs 14 days after the first paclitaxel injection. Small, 25%, medium, 36%; large, 39%. ( D – H ) Representative images of ISHH for Nt3 mRNA (red) and immunohistochemistry for different DRG cell markers (calcitonin gene-related peptide (CGRP; green; D ), neurofilament 200 (NF200; green; E ), isolectin B4 (IB4; green; F ), or tyrosine hydroxylase (TH; green; G )) in the L3/4 DRGs 14 days after the first paclitaxel injection. Arrows: double-labeling neurons. Statistical summary of number of double-labeling neurons ( H ). n = 9–12 sections from three mice. Scale bar: 50 µm. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Representative images of in situ hybridization histochemistry (ISHH) for Nt3 mRNA (red) and immunohistochemistry for β-tubulin III (green; A ) or glutamine synthetase (GS; green; B ) in the L3/4 DRGs 14 days after the first paclitaxel or vehicle injection. Cellular nuclei were labeled by 4’, 6-diamidino-2- phenylindole (DAPI; blue). n = 9–12 sections from three mice/group. * P < 0.05 by two-tailed unpaired Student t test. Scale bars: 50 µm. ( C ) Size distribution of Nt3 mRNA-labeled neuronal somata in the L3/4 DRGs 14 days after the first paclitaxel injection. Small, 25%, medium, 36%; large, 39%. ( D – H ) Representative images of ISHH for Nt3 mRNA (red) and immunohistochemistry for different DRG cell markers (calcitonin gene-related peptide (CGRP; green; D ), neurofilament 200 (NF200; green; E ), isolectin B4 (IB4; green; F ), or tyrosine hydroxylase (TH; green; G )) in the L3/4 DRGs 14 days after the first paclitaxel injection. Arrows: double-labeling neurons. Statistical summary of number of double-labeling neurons ( H ). n = 9–12 sections from three mice. Scale bar: 50 µm. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: In Situ Hybridization, Immunohistochemistry, Injection, Labeling, Two Tailed Test

Data: mean ± SD. ( A ) Expression of NT3 protein in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or NC siRNA-microinjected male mice. n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( B – H ) Paw withdrawal frequency to 0.07 g ( B , F ) and 0.4 g ( C , G ) von Frey filament stimuli and paw withdrawal latency to heat ( D , H ) and cold ( E ) stimuli on the ipsilateral ( B – E ) and contralateral ( F – H ) side on days as indicated from male mice with DRG microinjection of NT3 siRNA or NC siRNA 7 days after the first injection of paclitaxel (PTX) or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel plus NC siRNA-treated group at the corresponding time points by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( I ) Levels of p-ERK1/2, total ERK1/2, and GFAP in the ipsilateral L3/4 dorsal horn 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from male mice with DRG microinjection of NT3 siRNA or NC siRNA. n = 3 mice/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by Tukey post hoc test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A ) Expression of NT3 protein in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or NC siRNA-microinjected male mice. n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( B – H ) Paw withdrawal frequency to 0.07 g ( B , F ) and 0.4 g ( C , G ) von Frey filament stimuli and paw withdrawal latency to heat ( D , H ) and cold ( E ) stimuli on the ipsilateral ( B – E ) and contralateral ( F – H ) side on days as indicated from male mice with DRG microinjection of NT3 siRNA or NC siRNA 7 days after the first injection of paclitaxel (PTX) or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel plus NC siRNA-treated group at the corresponding time points by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( I ) Levels of p-ERK1/2, total ERK1/2, and GFAP in the ipsilateral L3/4 dorsal horn 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from male mice with DRG microinjection of NT3 siRNA or NC siRNA. n = 3 mice/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by Tukey post hoc test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Expressing, Injection, Microinjection

Data: mean ± SD. ( A ) Expression of NT3 protein in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or NC siRNA-microinjected female mice. n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( B – H ) Paw withdrawal frequency to 0.07 g ( B , F ) and 0.4 g ( C , G ) von Frey filament stimuli and paw withdrawal latency to heat ( D , H ) and cold ( E ) stimuli on the ipsilateral ( B – E ) and contralateral ( F – H ) side on the days as indicated from female mice with DRG microinjection of NT3 siRNA or NC siRNA on day 7 after the first injection of paclitaxel or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel plus NC siRNA-treated group at the corresponding time points by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( I ) Levels of p-ERK1/2, total ERK1/2, and GFAP in the ipsilateral L3/4 dorsal horn 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from female mice with DRG microinjection of NT3 siRNA or NC siRNA. n = 3 mice/group. ** P < 0.01 by two-way ANOVA followed by Tukey post hoc test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A ) Expression of NT3 protein in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or NC siRNA-microinjected female mice. n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( B – H ) Paw withdrawal frequency to 0.07 g ( B , F ) and 0.4 g ( C , G ) von Frey filament stimuli and paw withdrawal latency to heat ( D , H ) and cold ( E ) stimuli on the ipsilateral ( B – E ) and contralateral ( F – H ) side on the days as indicated from female mice with DRG microinjection of NT3 siRNA or NC siRNA on day 7 after the first injection of paclitaxel or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel plus NC siRNA-treated group at the corresponding time points by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( I ) Levels of p-ERK1/2, total ERK1/2, and GFAP in the ipsilateral L3/4 dorsal horn 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from female mice with DRG microinjection of NT3 siRNA or NC siRNA. n = 3 mice/group. ** P < 0.01 by two-way ANOVA followed by Tukey post hoc test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Expressing, Injection, Microinjection

Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the L3/4 DRGs 28 days after the first intraperitoneal (i.p.) injection of paclitaxel (PTX) or vehicle (Veh) from the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. n = 3 biological repeated (3 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( C – I ) Paw withdrawal frequency to 0.07 g ( C , G ) and 0.4 g ( D , H ) von Frey filament stimuli and paw withdrawal latency to heat ( E , I ) and cold ( F ) stimuli on the left ( C – F ) and right ( G – I ) side on days as indicated from NT3 f/f mice and NT3 cKD with i.p. injection of tamoxifen (Tam) daily for 7 consecutive days starting at day 7 after the first i.p. injection of paclitaxel (PTX) or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel-treated NT3 f/f mice at the corresponding days by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( J , K ) Spontaneous ongoing pain as assessed by the CPP test 21 days after the first i.p. injection of paclitaxel (PTX) or vehicle in the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. Time spent in each chamber ( J ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( K ). n = 9 mice/group. ** P < 0.01 by three-way ANOVA with repeated measures followed by post hoc Tukey test ( J ) or by two-way ANOVA followed by Tukey post hoc test ( K ). ( L ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the L3/4 dorsal horn 28 days after the first i.p. injection of paclitaxel (PTX) or vehicle in the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. n = 3 mice/group. * P < 0.05, ** P < 0 . 01 by two-way ANOVA followed by post hoc Tukey test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the L3/4 DRGs 28 days after the first intraperitoneal (i.p.) injection of paclitaxel (PTX) or vehicle (Veh) from the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. n = 3 biological repeated (3 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( C – I ) Paw withdrawal frequency to 0.07 g ( C , G ) and 0.4 g ( D , H ) von Frey filament stimuli and paw withdrawal latency to heat ( E , I ) and cold ( F ) stimuli on the left ( C – F ) and right ( G – I ) side on days as indicated from NT3 f/f mice and NT3 cKD with i.p. injection of tamoxifen (Tam) daily for 7 consecutive days starting at day 7 after the first i.p. injection of paclitaxel (PTX) or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel-treated NT3 f/f mice at the corresponding days by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( J , K ) Spontaneous ongoing pain as assessed by the CPP test 21 days after the first i.p. injection of paclitaxel (PTX) or vehicle in the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. Time spent in each chamber ( J ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( K ). n = 9 mice/group. ** P < 0.01 by three-way ANOVA with repeated measures followed by post hoc Tukey test ( J ) or by two-way ANOVA followed by Tukey post hoc test ( K ). ( L ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the L3/4 dorsal horn 28 days after the first i.p. injection of paclitaxel (PTX) or vehicle in the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. n = 3 mice/group. * P < 0.05, ** P < 0 . 01 by two-way ANOVA followed by post hoc Tukey test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Injection

Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the ipsilateral L3/4 DRGs 8 weeks after microinjection of AAV5-NT3 or control AAV5-GFP in male mice. n = 3 biological repeats (6 mice)/group. ** P < 0.01 by two-tailed unpaired Student t test. ( C – F ) Paw withdrawal frequency to 0.07 g ( C ) and 0.4 g ( D ) von Frey filament stimuli and paw withdrawal latency to heat ( E ) and cold ( F ) stimuli on the ipsilateral and contralateral sides on weeks as indicated after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-GFP group on the ipsilateral side at the corresponding time points by three-way ANOVA with repeated measures followed by Tukey post hoc test. ( G , H ) Spontaneous ongoing pain as assessed by the CPP test 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. Time spent in each chamber ( G ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( H ). n = 9 mice/group. ** P < 0.01 by two-way ANOVA with repeated measures followed by post hoc Tukey test ( G ) or by two-tailed unpaired Student t test ( H ). ( I ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 3 mice/group. ** P < 0.01 by two-tailed unpaired Student t test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the ipsilateral L3/4 DRGs 8 weeks after microinjection of AAV5-NT3 or control AAV5-GFP in male mice. n = 3 biological repeats (6 mice)/group. ** P < 0.01 by two-tailed unpaired Student t test. ( C – F ) Paw withdrawal frequency to 0.07 g ( C ) and 0.4 g ( D ) von Frey filament stimuli and paw withdrawal latency to heat ( E ) and cold ( F ) stimuli on the ipsilateral and contralateral sides on weeks as indicated after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-GFP group on the ipsilateral side at the corresponding time points by three-way ANOVA with repeated measures followed by Tukey post hoc test. ( G , H ) Spontaneous ongoing pain as assessed by the CPP test 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. Time spent in each chamber ( G ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( H ). n = 9 mice/group. ** P < 0.01 by two-way ANOVA with repeated measures followed by post hoc Tukey test ( G ) or by two-tailed unpaired Student t test ( H ). ( I ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 3 mice/group. ** P < 0.01 by two-tailed unpaired Student t test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Microinjection, Control, Two Tailed Test

Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the ipsilateral L3/4 DRGs 8 weeks after microinjection of AAV5-NT3 or control AAV5-GFP in female mice. n = 3 biological repeats (6 mice)/group. ** P < 0.01 by two-tailed unpaired Student t test. ( C – F ) Paw withdrawal frequency to 0.07 g ( C ) and 0.4 g ( D ) von Frey filament stimuli and paw withdrawal latency to heat ( E ) and cold ( F ) stimuli on the ipsilateral and contralateral sides on weeks as indicated after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-GFP group on the ipsilateral side at the corresponding time points by three-way ANOVA with repeated measures followed by the Tukey post hoc test. ( G , H ) Spontaneous ongoing pain as assessed by the CPP test 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. Time spent in each chamber ( G ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( H ). n = 9 mice/group. ** P < 0.01 by two-way ANOVA with repeated measures followed by post hoc Tukey test ( G ) or by two-tailed unpaired Student t test ( H ). ( I ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 3 mice/group. ** P < 0.01 by two-tailed unpaired Student t test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the ipsilateral L3/4 DRGs 8 weeks after microinjection of AAV5-NT3 or control AAV5-GFP in female mice. n = 3 biological repeats (6 mice)/group. ** P < 0.01 by two-tailed unpaired Student t test. ( C – F ) Paw withdrawal frequency to 0.07 g ( C ) and 0.4 g ( D ) von Frey filament stimuli and paw withdrawal latency to heat ( E ) and cold ( F ) stimuli on the ipsilateral and contralateral sides on weeks as indicated after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-GFP group on the ipsilateral side at the corresponding time points by three-way ANOVA with repeated measures followed by the Tukey post hoc test. ( G , H ) Spontaneous ongoing pain as assessed by the CPP test 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. Time spent in each chamber ( G ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( H ). n = 9 mice/group. ** P < 0.01 by two-way ANOVA with repeated measures followed by post hoc Tukey test ( G ) or by two-tailed unpaired Student t test ( H ). ( I ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 3 mice/group. ** P < 0.01 by two-tailed unpaired Student t test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Microinjection, Control, Two Tailed Test

Data: mean ± SD. ( A , B ) Levels of Nt3 , TrkC , and p75 NTR mRNAs ( A ) and their respective proteins ( B ) in the ipsilateral L3/4 DRGs 42 days after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si). n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( C – I ) Paw withdrawal frequencies to 0.07 g ( C , G ) and 0.4 g ( D , H ) von Frey filament stimuli and paw withdrawal latencies to heat ( E, I ) and cold stimuli ( F ) on the ipsilateral ( C – F ) and contralateral ( G – I ) sides on days as indicated after AAV-NT3 or AAV-GFP microinjection in the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si) starting at 35 days after AAV5 microinjection. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-NT3 plus control scrambled siRNA-treated group at the corresponding days by two-way ANOVA with repeated measures followed by Tukey post hoc test. ( J ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn on day 42 after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si). n = 3 mice/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by Tukey post hoc test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Levels of Nt3 , TrkC , and p75 NTR mRNAs ( A ) and their respective proteins ( B ) in the ipsilateral L3/4 DRGs 42 days after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si). n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( C – I ) Paw withdrawal frequencies to 0.07 g ( C , G ) and 0.4 g ( D , H ) von Frey filament stimuli and paw withdrawal latencies to heat ( E, I ) and cold stimuli ( F ) on the ipsilateral ( C – F ) and contralateral ( G – I ) sides on days as indicated after AAV-NT3 or AAV-GFP microinjection in the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si) starting at 35 days after AAV5 microinjection. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-NT3 plus control scrambled siRNA-treated group at the corresponding days by two-way ANOVA with repeated measures followed by Tukey post hoc test. ( J ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn on day 42 after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si). n = 3 mice/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by Tukey post hoc test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Microinjection, Control

Data: mean ± SD. Data: mean ± SD. ( A – C ) Levels of CCL2 and TrkC proteins in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or negative control scrambled siRNA (NC siRNA)-microinjected male ( A ) and female ( B ) mice or 28 days after the first injection of paclitaxel or vehicle from the tamoxifen-treated NT3 f/f mice and NT3 cKD mice ( C ). n = 3 biological repeats (6 mice in A and B and 3 mice in C)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( D ) Level of CCL2 protein in the ipsilateral L3/4 DRGs 42 days after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), or TrkC siRNA (TrkC-si). n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( E – H ) Levels of Nt3 mRNA ( E , G ), Ccl2 mRNA ( E , G ) and their respective proteins ( F , H ) in the cultured DRG neurons (E-F) or in human neuroblastoma cell lines ( G , H ) with transfection of NT3 siRNA or negative control scrambled siRNA (NC siRNA) plus with exposure to paclitaxel (PTX) or vehicle (Veh). n = 3 biological repeats. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( I , J ) Levels of Nt3 mRNA ( I ), Ccl2 mRNA ( I ) and their respective proteins ( J ) in the cultured DRG neurons with transduction of AAV5-NT3 (NT3) or AAV5-GFP (GFP) plus with transfection of NT3 siRNA or negative control scrambled siRNA (NC siRNA). n = 3 biological repeats. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. Data: mean ± SD. ( A – C ) Levels of CCL2 and TrkC proteins in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or negative control scrambled siRNA (NC siRNA)-microinjected male ( A ) and female ( B ) mice or 28 days after the first injection of paclitaxel or vehicle from the tamoxifen-treated NT3 f/f mice and NT3 cKD mice ( C ). n = 3 biological repeats (6 mice in A and B and 3 mice in C)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( D ) Level of CCL2 protein in the ipsilateral L3/4 DRGs 42 days after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), or TrkC siRNA (TrkC-si). n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( E – H ) Levels of Nt3 mRNA ( E , G ), Ccl2 mRNA ( E , G ) and their respective proteins ( F , H ) in the cultured DRG neurons (E-F) or in human neuroblastoma cell lines ( G , H ) with transfection of NT3 siRNA or negative control scrambled siRNA (NC siRNA) plus with exposure to paclitaxel (PTX) or vehicle (Veh). n = 3 biological repeats. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( I , J ) Levels of Nt3 mRNA ( I ), Ccl2 mRNA ( I ) and their respective proteins ( J ) in the cultured DRG neurons with transduction of AAV5-NT3 (NT3) or AAV5-GFP (GFP) plus with transfection of NT3 siRNA or negative control scrambled siRNA (NC siRNA). n = 3 biological repeats. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Injection, Negative Control, Microinjection, Control, Cell Culture, Transfection, Transduction

Co-expression analysis of Nt3 mRNA, TrkC mRNA and Ccl2 mRNA in individual large (>35 μm in diameter; A ), medium (25–35 µm in diameter; B ), and small (<25 μm in diameter; C ) DRG neurons from naive mice ( n = 2) by single-cell RT-PCR assay. NeuN mRNA is used as a neuronal marker. Tuba-1α mRNA is used as a loading control. M DNA ladder marker, NC no cDNA. n = 5 neurons/size. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Co-expression analysis of Nt3 mRNA, TrkC mRNA and Ccl2 mRNA in individual large (>35 μm in diameter; A ), medium (25–35 µm in diameter; B ), and small (<25 μm in diameter; C ) DRG neurons from naive mice ( n = 2) by single-cell RT-PCR assay. NeuN mRNA is used as a neuronal marker. Tuba-1α mRNA is used as a loading control. M DNA ladder marker, NC no cDNA. n = 5 neurons/size. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Marker, Control

Clinical characteristics of subjects.

Journal: EBioMedicine

Article Title: Molecular mechanisms underlying altered neurobehavioural development of female offspring of mothers with polycystic ovary syndrome: FOS-mediated regulation of neurotrophins in placenta

doi: 10.1016/j.ebiom.2020.102993

Figure Lengend Snippet: Clinical characteristics of subjects.

Article Snippet: Serum biochemical indexes including, total testosterone (TT) (80979, 0.05 ng/mL, Crystal Chem Inc, USA), sex hormone-binding globulin (SHBG) (RAB0734, 1.2 pmol/L, Sigma-Aldrich, USA), BDNF (RAB0026, 80 pg/mL, Sigma-Aldrich, USA), NGF (CSB-E04683h, 6.86pg/mL, Cusabio, USA), interleukin 6 (IL6) (BMS213-2, 0.92 pg/mL, Invitrogen, USA), and interleukin 15 (IL15) (BMS2106, 3.4 pg/mL, Invitrogen, USA) were measured with enzyme-linked immunosorbent assay (ELISA) in maternal peripheral blood and umbilical cord blood.

Techniques: Control

Brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in placental villi. (a) Visualization of BDNF and NGF in placental villi of polycystic ovarian syndrome (PCOS) and control group by immunofluorescence with BDNF (green) and NGF (red). Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue fluorescence). The syncytiotrophoblasts layers are labeled with white arrows, and the results of protein quantification are shown by bar plots (n = 5 in each group). All scale bars are 50 μm. BDNF and NGF mRNA expression level were quantified by real-time polymerase chain reaction (real-time PCR). PCOS: n = 20; control: n = 32. Data were presented as mean ± SEM. *P < 0.05, unpaired two-tailed Student's t tests. (b) The methylation status at the promoter region of BDNF (blue) and NGF (purple) genes in the placental villi from women with PCOS and controls using bisulfite genomic sequencing (BSP) (n = 3 in each group, significance was determined by Chi-square test).

Journal: EBioMedicine

Article Title: Molecular mechanisms underlying altered neurobehavioural development of female offspring of mothers with polycystic ovary syndrome: FOS-mediated regulation of neurotrophins in placenta

doi: 10.1016/j.ebiom.2020.102993

Figure Lengend Snippet: Brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in placental villi. (a) Visualization of BDNF and NGF in placental villi of polycystic ovarian syndrome (PCOS) and control group by immunofluorescence with BDNF (green) and NGF (red). Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue fluorescence). The syncytiotrophoblasts layers are labeled with white arrows, and the results of protein quantification are shown by bar plots (n = 5 in each group). All scale bars are 50 μm. BDNF and NGF mRNA expression level were quantified by real-time polymerase chain reaction (real-time PCR). PCOS: n = 20; control: n = 32. Data were presented as mean ± SEM. *P < 0.05, unpaired two-tailed Student's t tests. (b) The methylation status at the promoter region of BDNF (blue) and NGF (purple) genes in the placental villi from women with PCOS and controls using bisulfite genomic sequencing (BSP) (n = 3 in each group, significance was determined by Chi-square test).

Article Snippet: Serum biochemical indexes including, total testosterone (TT) (80979, 0.05 ng/mL, Crystal Chem Inc, USA), sex hormone-binding globulin (SHBG) (RAB0734, 1.2 pmol/L, Sigma-Aldrich, USA), BDNF (RAB0026, 80 pg/mL, Sigma-Aldrich, USA), NGF (CSB-E04683h, 6.86pg/mL, Cusabio, USA), interleukin 6 (IL6) (BMS213-2, 0.92 pg/mL, Invitrogen, USA), and interleukin 15 (IL15) (BMS2106, 3.4 pg/mL, Invitrogen, USA) were measured with enzyme-linked immunosorbent assay (ELISA) in maternal peripheral blood and umbilical cord blood.

Techniques: Derivative Assay, Control, Immunofluorescence, Fluorescence, Labeling, Expressing, Real-time Polymerase Chain Reaction, Two Tailed Test, Methylation, Genomic Sequencing

Identification of FOS and its regulation of neurotrophins in placenta of polycystic ovary syndrome (PCOS). (a) Heatmaps of the global DNA methylation in the promoter and gene expression data for placentae from women with PCOS and controls. (n = 3 in each group) (b) Scatter plot of global DNA methylation levels in placentae in controls (x-axis) compared to women with PCOS (y-axis). Point density is shown as blue shading; Peacock blue and purple dots indicate significant down-regulated and up-regulated cytosine phosphate guanine (CpG) sites associated with a methylation difference > 0.20. (c) Volcano plot to inspect differentially expressed genes in placentae from women with PCOS and controls, with fold change as the abscissa and -log10 (P value) as the ordinate. Peacock blue and purple splashes represent genes that significantly up or down regulated respectively. Gray splashes mean genes without significantly different expression. FOS gene is marked as red. (d) Gene Ontology (GO) terms enriched in differentially expressed genes in placentae from women with PCOS. (e) Neural GO terms enriched in differentially expressed gene (top) and methylated DNA (bottom) in placentae from women with PCOS. (f) FOS gene mRNA and protein expression levels in human placentae, as assessed by real-time polymerase chain reaction (real-time PCR) (PCOS: n = 20; control: n = 32) and immunofluorescence with FOS (green), and nuclear DNA (blue) labeling (n = 5 in each group). All scale bars are 50 μm. (g) The summary data of methylation status at the promoter region of FOS gene in the placental villi using bisulfite genomic sequencing (BSP) (n = 3 in each group, significance was determined by Chi-square test). (h) In silico analysis of the genomic DNA 5 kb upstream and downstream of BDNF (pIV) and NGF (pI) transcription start site (TSS). Detection of FOS (i) protein expression levels, BDNF (j) and NGF (k) mRNA expression levels in overexpression group (n = 3) and control group (n = 3). Data were presented as mean ± SEM. *P < 0.05, unpaired two-tailed Student's t tests.

Journal: EBioMedicine

Article Title: Molecular mechanisms underlying altered neurobehavioural development of female offspring of mothers with polycystic ovary syndrome: FOS-mediated regulation of neurotrophins in placenta

doi: 10.1016/j.ebiom.2020.102993

Figure Lengend Snippet: Identification of FOS and its regulation of neurotrophins in placenta of polycystic ovary syndrome (PCOS). (a) Heatmaps of the global DNA methylation in the promoter and gene expression data for placentae from women with PCOS and controls. (n = 3 in each group) (b) Scatter plot of global DNA methylation levels in placentae in controls (x-axis) compared to women with PCOS (y-axis). Point density is shown as blue shading; Peacock blue and purple dots indicate significant down-regulated and up-regulated cytosine phosphate guanine (CpG) sites associated with a methylation difference > 0.20. (c) Volcano plot to inspect differentially expressed genes in placentae from women with PCOS and controls, with fold change as the abscissa and -log10 (P value) as the ordinate. Peacock blue and purple splashes represent genes that significantly up or down regulated respectively. Gray splashes mean genes without significantly different expression. FOS gene is marked as red. (d) Gene Ontology (GO) terms enriched in differentially expressed genes in placentae from women with PCOS. (e) Neural GO terms enriched in differentially expressed gene (top) and methylated DNA (bottom) in placentae from women with PCOS. (f) FOS gene mRNA and protein expression levels in human placentae, as assessed by real-time polymerase chain reaction (real-time PCR) (PCOS: n = 20; control: n = 32) and immunofluorescence with FOS (green), and nuclear DNA (blue) labeling (n = 5 in each group). All scale bars are 50 μm. (g) The summary data of methylation status at the promoter region of FOS gene in the placental villi using bisulfite genomic sequencing (BSP) (n = 3 in each group, significance was determined by Chi-square test). (h) In silico analysis of the genomic DNA 5 kb upstream and downstream of BDNF (pIV) and NGF (pI) transcription start site (TSS). Detection of FOS (i) protein expression levels, BDNF (j) and NGF (k) mRNA expression levels in overexpression group (n = 3) and control group (n = 3). Data were presented as mean ± SEM. *P < 0.05, unpaired two-tailed Student's t tests.

Article Snippet: Serum biochemical indexes including, total testosterone (TT) (80979, 0.05 ng/mL, Crystal Chem Inc, USA), sex hormone-binding globulin (SHBG) (RAB0734, 1.2 pmol/L, Sigma-Aldrich, USA), BDNF (RAB0026, 80 pg/mL, Sigma-Aldrich, USA), NGF (CSB-E04683h, 6.86pg/mL, Cusabio, USA), interleukin 6 (IL6) (BMS213-2, 0.92 pg/mL, Invitrogen, USA), and interleukin 15 (IL15) (BMS2106, 3.4 pg/mL, Invitrogen, USA) were measured with enzyme-linked immunosorbent assay (ELISA) in maternal peripheral blood and umbilical cord blood.

Techniques: DNA Methylation Assay, Gene Expression, Methylation, Expressing, Real-time Polymerase Chain Reaction, Control, Immunofluorescence, Labeling, Genomic Sequencing, In Silico, Over Expression, Two Tailed Test

MSM-DTM adsorbs inflammatory cytokines, suppresses TSPCs inflammation and senescence, and promotes tenogenic differentiation and migration (A) The remaining concentrations of TNF-α, IL-1β, IL-6, IFN-γ, LPS, and NGF were detected by ELISA after co-culture with different concentrations of MSM. (B and C) RT-qPCR of IL-6 and CCL-2 in TSPCs under different treatments. (D) Western blot of COL1A2, MMP3, and TNMD. (E) ELISA of TNF-α, IL-6, and IFN-γ in supernatants. (F)Western blot of p16 and p21 after 7 days of treatment. (G) β-Galactosidase staining analysis after 7 days of treatment. Scale bars, 100 μm. (H and I) Immunofluorescence and quantification of TNMD and TNC after 14-day treatment. Scale bars, 50 μm. (J) Relative mRNA expression of tenogenic differentiation markers SCX and TNC. (K and L) Representative images and quantification of Transwell assay. Scale bars, 100 μm. (M and N) Representative images and quantification of wound healing assay. Scale bars, 100 μm. Statistical comparisons were performed with one-way ANOVA with Tukey’s multiple comparisons test. Data are presented as the mean ± SD, n = 3. Ns, no significance, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 between groups.

Journal: Cell Reports Medicine

Article Title: A biomimetic hybrid membrane vesicle nanoplatform attenuates tendinopathy through neuroinflammation modulation and tendon regeneration

doi: 10.1016/j.xcrm.2026.102937

Figure Lengend Snippet: MSM-DTM adsorbs inflammatory cytokines, suppresses TSPCs inflammation and senescence, and promotes tenogenic differentiation and migration (A) The remaining concentrations of TNF-α, IL-1β, IL-6, IFN-γ, LPS, and NGF were detected by ELISA after co-culture with different concentrations of MSM. (B and C) RT-qPCR of IL-6 and CCL-2 in TSPCs under different treatments. (D) Western blot of COL1A2, MMP3, and TNMD. (E) ELISA of TNF-α, IL-6, and IFN-γ in supernatants. (F)Western blot of p16 and p21 after 7 days of treatment. (G) β-Galactosidase staining analysis after 7 days of treatment. Scale bars, 100 μm. (H and I) Immunofluorescence and quantification of TNMD and TNC after 14-day treatment. Scale bars, 50 μm. (J) Relative mRNA expression of tenogenic differentiation markers SCX and TNC. (K and L) Representative images and quantification of Transwell assay. Scale bars, 100 μm. (M and N) Representative images and quantification of wound healing assay. Scale bars, 100 μm. Statistical comparisons were performed with one-way ANOVA with Tukey’s multiple comparisons test. Data are presented as the mean ± SD, n = 3. Ns, no significance, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 between groups.

Article Snippet: The remaining cytokines in the supernatant were quantified using ELISA kits for TNF-α (ABclonal, China), IL-1β (ABclonal, China), IL-6 (ABclonal, China), IFN-γ (ABclonal, China), and NGF (ABclonal, China), and LPS (ABclonal, China), following the manufacturers’ protocols.

Techniques: Migration, Enzyme-linked Immunosorbent Assay, Co-Culture Assay, Quantitative RT-PCR, Western Blot, Staining, Immunofluorescence, Expressing, Transwell Assay, Wound Healing Assay

Journal: Cell Reports Medicine

Article Title: A biomimetic hybrid membrane vesicle nanoplatform attenuates tendinopathy through neuroinflammation modulation and tendon regeneration

doi: 10.1016/j.xcrm.2026.102937

Figure Lengend Snippet:

Article Snippet: The remaining cytokines in the supernatant were quantified using ELISA kits for TNF-α (ABclonal, China), IL-1β (ABclonal, China), IL-6 (ABclonal, China), IFN-γ (ABclonal, China), and NGF (ABclonal, China), and LPS (ABclonal, China), following the manufacturers’ protocols.

Techniques: Recombinant, Lysis, Hydroxyproline Assay, Enzyme-linked Immunosorbent Assay, Isolation, SYBR Green Assay, Bicinchoninic Acid Protein Assay, Staining, Software